What Bachem’s Flat Share Performance Says About Peptide CDMOs

Why Share Performance Is a Weak Proxy for Supply-Partner Value

Revenue growth is often carried by a mix that says little about your program. Development-phase work expands with pipeline flow and consumes capacity in small, flexible increments; commercial API supply depends on long-qualified lines running at stable utilization. A vendor can post a strong growth number while the segment you need is contracting — and above, it was.

Capital expenditure is a promise, not a capability. Announced capacity needs commissioning, qualification, and staffing before it can release material. Global peptide CDMO capacity investment reached a five-year high in 2026, crossing roughly USD 2.4 billion by mid-year, but the binding constraint is talent — process chemistry, lyophilization engineering, QA/QC — rather than steel.

Utilization figures are aggregate, not personal. US peptide CDMO capacity ran at roughly 78–85% in 2026, tighter in commercial-scale GLP-1 work — above the point where demand-driven delays start hitting clinical timelines, below the roughly 90% threshold where downstream bottlenecks raise quality risk. Neither end of that band tells you whether your slot exists.

None of this makes large vendors poor choices. For capital-intensive commercial API programs, a broad regulatory footprint and multi-site supply, scale is often decisive. The point is narrower: size is a hypothesis about your program, not a conclusion. The four pillars below are how you test it.

A Scoring Matrix for the Four Value Pillars

The framework below is built for peptide supplier evaluation — it treats supplier value as four independently verifiable dimensions. Financial scale does not appear as a criterion, because no amount of it substitutes for any of them.

Weights shift with program stage: discovery screening should weight technical depth and turnaround, while IND-enabling and commercial programs should weight quality consistency and capacity transparency far more heavily. What should not shift is the requirement for evidence on all four.

Quality Consistency and Lot-to-Lot Consistency — Verifiable, Not Aspirational

Quality consistency means successive production batches of the same peptide match within predefined limits for identity, puhtus, impurity profile, and performance-relevant attributes. It is not a statement of intent. It is a documented, auditable property of a control system.

The documents that carry the evidence

A certificate of analysis is only as useful as its specificity: is the CoA tied to the exact lot you received, and is the underlying data readable rather than summarized? Reverse-phase HPLC is the standard purity readout, typically detected at 214–220 nm, but the chromatogram, column, and gradient should be visible — not just a percentage. Orthogonal identity confirmation comes from ESI-MS or MALDI-MS tied to the same lot. Depending on use case, the release panel may extend to water and counterion content, residual solvents under ICH Q3C(R9), endotoxin by USP ⟨85⟩ testing, sterility, and amino acid analysis.

Specifications should be defined in the attribute categories regulators expect — identity, puhtus, impurities, content or strength, plus relevant physicochemical characteristics — following ICH Q6B specification principles. In the EU, the EMA’s guideline on the development and manufacture of synthetic peptides, adopted December 2025 and effective 1 June 2026, sets peptide-specific expectations for process, characterisation, specifications, and analytical control. A partner who maps your program onto that structure is demonstrating control; one who cannot is describing intentions.

What lot-to-lot actually means

Consistency is a band, not a number. A purity series reading 95%, 92%, 98%, 88% across successive lots without explanation is not manufacturing noise — it is a control-system signal. The useful question is not “what is your typical purity?” but “show me five consecutive lots of a comparable peptide, side by side.”

Two habits separate rigorous buyers from hopeful ones. Keep every batch-specific certificate and treat it as a data point, not a disposable PDF. Then compare each new lot against your own historical lots — purity, secondary-peak fingerprint, retention-time behaviour — rather than the certificate’s headline figure. For filing-bound programs, an IND-enabling package typically presents batch analysis across at least three consecutive lots, with area-percent purity consistency within roughly ±1.0% and matching impurity fingerprints.

Verification checklist

Peptide Manufacturing Capacity Transparency — Five Different Numbers Called “Capacity”

Capacity transparency means a supplier separates what is announced from what is installed, what is qualified from what is available to you, and can commit the difference in writing. For most buyers this is the most consequential gap between a deck and a contract.

Nameplate, installed, qualified, committed

Peptiidide süntees Capacity is not one figure. Ask for it in tiers.

A supplier that answers only at the nameplate level is not necessarily evasive — most organizations do not publish tier-separated figures. Ask anyway — the quality of the answer is itself the signal.

The downstream bottlenecks that set the real ceiling

Synthesis capacity is rarely the true constraint. For many complex or high-volume peptides, deliverable volume is governed by preparative reverse-phase HPLC — column inventory, pass count, diameter — plus lyophilization Synthetic Peptides throughput, solvent recovery, cold storage, and analytical suite availability. Prep-HPLC suite count and column diameter are a more direct proxy for usable clinical-grade output than reactor volume.

⚠️ Hoiatus: Because utilization in the mid-80% range leaves little slack, reserving a slot against announced rather than qualified capacity is one of the most common — and most expensive — procurement errors in peptide programs.

Turning capacity into a contractual commitment

Capacity becomes reliable only when it is written into governing documents. Lead-time reality first: capacity reservation at leading peptide CDMOs now runs in the 18–24 month range for commercial-scale work, well beyond the 6–12 month norms of 2019–2021.

The quality agreement defines responsibilities otherwise left to project-level improvisation: batch records, release testing, records retention, audit rights, change control, deviation closure, and regulatory support. The service-level schedule quantifies performance — on-time-in-full delivery, right-first-time execution, deviation closure times, release timing, escalation response — and states what happens when a threshold is missed. A common commercial benchmark for on-time, in-full delivery is 95% or higher, with remediation defined in the contract rather than negotiated after a failure. Business continuity language covers redundancy, backup suppliers, and constraints at the specific site named in your proposal.

If your program carries real risk, a qualified secondary route is not a sign of distrust — it is the standard structure of resilient peptide supply, and it belongs before the first campaign, not after the first delay. Partners who support peptide process development from route selection through scale-up can discuss continuity alongside capacity. Peptiidide tootmine

Verification checklist

Technical Depth — Where “We Can Do It” Becomes Evidence

Technical depth means demonstrated ability to solve sequence-specific problems, not a catalogue of reaction types. The distinction matters because the peptides that fail are rarely the easy ones.

The sequence-level test cases

Depth is testable against specific difficulty classes: long chains; aggregation-prone or hydrophobic segments that resist coupling and purification; multiple disulfide bridges needing controlled oxidative folding; cyclization and stapling chemistry; non-natural and D-amino acid residues; and conjugates of peptide to protein, payload, or polymer. Separating closely eluting isomers and deletion by-products is its own competence — frequently the one that decides whether a program meets its timeline.

Scale is necessary for capital-intensive commercial API work — a dedicated large-scale SPPS suite with purification and analytical infrastructure is a substantial capital commitment. It is not evidence that your sequence can be made. Route selection, resin and loading strategy, impurity risk assessment, and purification planning are sequence-specific judgements, and hard programs are won or lost on them.

Regulatory literacy as a readout of chemistry depth

Ask how a program maps onto applicable guidance. The EMA synthetic-peptide guideline covers process, characterisation, specifications, and analytical control in peptide-specific terms. ICH Q6B specification principles define the attribute categories behind a defensible release strategy, ja ICH Q3C(R9) on residual solvents sets limits that peptide manufacturing routinely approaches given solvent volumes. A supplier who discusses these fluently is describing control; one who deflects to marketing language is disclosing its absence.

Whether the chemistry runs on solid-phase synthesis, microbial fermentation, or a hybrid route should follow from the sequence rather than a preferred platform. A custom peptide synthesis partner who works across both — and across modification classes spanning 300+ functional-group options — can choose the route the molecule needs. A supplier locked into one platform will route your peptide through it regardless.

CTA: Have a sequence that failed elsewhere? Send the sequence and the specific failure mode — a technical review of the route and purification strategy is more useful than a capability brochure.

Verification checklist

Customer Outcomes — Documentation You Can Verify

The final pillar replaces claims with records. It is the cheapest to check and the one most often skipped because asking for it can feel adversarial. Treat it as due diligence instead: you are verifying records, not challenging intentions.

Review history beats certificate counts

Ask for review history rather than certification counts: named programs where the supplier’s impurity-control strategy was reviewed and accepted, in which markets, what deficiency questions were raised, and how they were answered. Certificate counts describe paperwork; deficiency-and-response history describes capability under scrutiny. A complementary signal is publication footprint — peer-reviewed work in the last three years demonstrating synthesis of peptides with comparable length, hydrophobicity, or modification complexity.

The reference questions that surface real risk

Reference calls tend to produce reassurance because they ask reassuring questions. Four better ones:

1. How accurate were the original transfer and first-batch timelines once real data and documentation handoff began?

2. Did the supplier surface site-level capacity or material constraints early enough to protect the development plan?

3. How were deviations, CAPAs, and change controls handled when the program was under operational stress?

4. Which costs or responsibilities only became visible after contracting — analytical work, validation, storage?

The fourth question is the one most likely to change a decision: analytical development, validation, and storage are where budget expectations most often move after contracting. A supplier who pre-empts those items has run programs before, and is not learning on yours.

Analytical posture matters too. Organizations that run peptide testing and analytics alongside manufacturing are inviting scrutiny of their own release data — the posture you want from a partner whose certificate you are about to rely on.

Verification checklist

Must-Haves, Red Flags, and Your Self-Assessment Scorecard

Must-haves — walk away if unmet: lot-specific, unredacted certificates with orthogonal analytical data for the lots you will use; a quality agreement covering batch records, change control, deviation closure, and audit rights; the specific site and line that will produce your material; a named technical contact with authority over the route; ja, for clinical-stage work, batch data across consecutive lots with stable impurity fingerprints.

Red flags — investigate before proceeding: inability to name the exact site, line, or recent comparable programs; vague proposals around failed batches, capacity holds, or extra validation work; “end-to-end” claims that hide third-party steps; reference customers describing late surprises on deviations, scheduling, or documentation; purity figures that move across lots without explanation.

Tolerable gaps — price accordingly: longer lead times at a smaller specialist, often offset by faster technical response; a narrower regulatory footprint, acceptable for discovery and many preclinical programs; less automation, frequently offset by direct access to the scientists running your campaign.

Now score. Rate shortlisted partners from 1 juurde 5 on each row, weighting the rows to your program stage before you total them. The weights, not the raw scores, are what most buyers get wrong.

One interpretation rule matters more than the totals: a score of 4 või 5 on technical depth with a 2 on quality consistency is the most dangerous profile in the table. It describes a vendor capable of an impressive first campaign and unable to reproduce it. Weight accordingly.

What to Do First

Võtme kaasavõtt: A rolling forecast, a documented dual-source decision, and a documentation audit — in that order — resolve more supplier risk than any negotiation tactic applied later.

Start with a rolling forecast. Map peptide demand across the next 18–24 months — batch sizes and quality categories included — and give shortlisted suppliers that picture before requesting quotes. Forecast clarity is the most effective way to get a real answer on slot availability, because it lets a supplier respond to a concrete plan rather than a hypothetical.

Then make the dual-sourcing decision deliberately, before capacity pressure forces it. Decide which programs can tolerate a single source, then qualify a secondary route for those that cannot. Qualifying a supplier against a deadline costs materially more than qualifying one on your own schedule.

Finally, audit documentation before anything else: lot-specific certificates, trend data on comparable peptides, and the quality agreement and SLA templates that will govern the relationship. Most supplier risk is visible in documents, and documents can be reviewed without a site visit or a purchase order.

When you are ready to move from evaluation to execution, partners who can speak to route, scale, and release strategy in the same conversation make the transition shorter. MOL Changes runs that conversation across kohandatud peptiidide süntees, analytical verification, sterile manufacturing, and scale-up — or bring a specific sequence and its constraints to a technical discussion. That is a faster route to a decision than another round of capability slides.